



CELLUMEN EXPANDS DISCOVERY TOXICOLOGY SERVICES WITH CARDIAC HYPERTROPHY PANEL

First Cellular Systems Biology panel to detect development-limiting toxicities in cardiac cells

Pittsburgh, PA, December 17, 2008 – [Cellumen](#), a discovery toxicology company, today announced a new Cellular Systems Biology (CSB) panel to predict cardiac hypertrophy earlier in the drug discovery and development process. By integrating this new panel into Cellumen’s [CellCiphr Discovery Toxicology](#) profiling services, drug companies can now save millions of dollars in development costs that are typically wasted by not identifying toxic compounds earlier.

“In the past 10 years, nearly 30 percent of all drugs in the United States have been withdrawn due to cardiotoxicity,” says [Dr. Kate Johnston](#), Chief Scientific Officer and Vice President of Discovery Programs at Cellumen. “There are many tests available to detect electrophysiological abnormalities of the heart, but Cellumen’s Cardiac Hypertrophy Panel is the first systems-based panel to detect other development-limiting toxicities in cardiac cells.”

Cellumen’s Cardiac Hypertrophy Panel is designed to simultaneously measure eight distinct toxicity indicators in drug compounds including mitochondrial function, oxidative stress, apoptosis, and cellular hypertrophy. By leveraging Cellumen’s unique discovery toxicology approach, the panel quantifies both the mechanism and time course of toxicity. In addition, the proprietary CellCiphr Classifier, an integral component of the panel, provides a quick, objective means to identify compounds that may cause cardiac-specific toxicity.

“The CellCiphr Cardiac Hypertrophy panel is the next step in helping the FDA realize their goal to first minimize and then to replace animal testing within the next 10 years,” says [D. Lansing Taylor](#), PhD, CEO of Cellumen. “By continuing to broaden its predictive panels across target organs, Cellumen is bringing its unique Cellular Systems Biology approach to more therapeutic programs and enabling more pharmaceutical companies to determine toxicity while reducing the reliance on animal tests. In turn, we are helping these companies not only reduce the percentage of available therapies that get withdrawn from the market for safety issues, but also significantly cut costs associated with drug discovery and development.”

About Cellumen

Cellumen is the leading innovator in Cellular Systems Biology (CSB™) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen’s CSB solutions are driving Discovery Toxicology by addressing the full complexity of disease and safety. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of [Safeguard Scientifics](#). Other investors include [Novitas Capital](#), the [Pittsburgh Life Sciences Greenhouse](#) and [Innovation Works](#). For more information about Cellumen, please visit www.cellumen.com.

Cellumen Media Contact

Theresa Murray
Gregory FCA
610-642-8253 x164
Theresa@GregoryFCA.com